4-(methylthio)-2-piperazin-1-yl-1,3-benzothiazole

Catalog No. :
ACGTBI093
CAS No. :
1105194-64-6
Molecular Formula :
C12H15N3S2
Molecular Weight :
265.41

IUPAC Name:4-(methylthio)-2-(piperazin-1-yl)benzo[d]thiazole

4-(methylthio)-2-piperazin-1-yl-1,3-benzothiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$350.00Login to see priceInquiryInquiry
1g95%$1050.00Login to see priceInquiryInquiry
5g95%$3152.00Login to see priceInquiryInquiry
10g95%$4420.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(methylthio)-2-piperazin-1-yl-1,3-benzothiazole
IUPAC Name4-(methylthio)-2-(piperazin-1-yl)benzo[d]thiazole
Molecular FormulaC12H15N3S2
Molecular Weight265.41
SMILESCSC1=C2N=C(N3CCNCC3)SC2=CC=C1
InChI KeyGJCBVNFFVGDNOM-UHFFFAOYSA-N
Synonym4-(Methylthio)-2-piperazin-1-yl-1,3-benzothiazole;Benzothiazole, 4-(methylthio)-2-(1-piperazinyl)-;4-(methylthio)-2-(piperazin-1-yl)benzo[d]thiazole
CAS No.1105194-64-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACGTBI093 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. ACVDLC502 route compound structure diagram
    ACVDLC5021706440-01-8 In Stock
  4. Then
  5. ACGTBI093 route product structure diagram
    ACGTBI0931105194-64-6
Inquiry

2. ACGTBI093 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGTBI093 route product structure diagram
    ACGTBI0931105194-64-6
Inquiry

Comments (0)